Companies
Alnylam
the leading RNAi company; AMVUTTRA (vutrisiran) is approved for both forms of ATTR amyloidosis, with the first quarter of 2026 marking one year since the U.S. ATTR-CM launch — a significant commercial milestone;…
- Country
- United States
- Ticker
- ALNY
Commercial
siRNA (GalNAc)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2002-06-14 | alnylampharmaceuticalsinc.gcs-web.com · investors.alnylam.com · sec.gov |
| Headcount | 2,569 employees worldwide as of March 2026 | investors.alnylam.com |
| Revenue | $1,036,127,000 in net product revenues for Q1 2026 | alnylampharmaceuticalsinc.gcs-web.com · investors.alnylam.com |
| Regulatory approval | AMVUTTRA approved by FDA for ATTR-CM in March 2025 and for hATTR-PN in June 2022 | amyloidosis.org · investors.alnylam.com · sec.gov |
| Production site | manufacturing facility in Norton, Massachusetts | alnylam.com |
| Capacity | Initiated expansion of Norton facility to increase production capacity for RNAi therapeutics | alnylam.com |
Independent sources: amyloidosis.org · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Nucleic acid therapeutics (oligonucleotides) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.